60 Degrees Pharmaceuticals (NASDAQ:SXTP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) to a sell rating in a report published on Saturday morning.

Several other analysts have also recently issued reports on the company. HC Wainwright upped their target price on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, December 29th. Finally, Ascendiant Capital Markets lowered their price target on shares of 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating on the stock in a research report on Friday, November 28th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, 60 Degrees Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $17.60.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $1.83 on Friday. 60 Degrees Pharmaceuticals has a one year low of $1.36 and a one year high of $17.68. The stock has a market cap of $1.94 million, a PE ratio of -0.13 and a beta of 3.01. The stock has a 50 day moving average price of $3.11 and a 200 day moving average price of $4.07.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.